Extracorporeal Photopheresis versus Anticytokine Therapy as a Second-Line Treatment for Steroid-Refractory Acute GVHD: A Multicenter Comparative Analysis

被引：67

作者：

Jagasia, Madan ^{[1
]}

Greinix, Hildegard ^{[2
]}

Robin, Marie ^{[3
]}

Das-Gupta, Emma ^{[4
]}

Jacobs, Ryan ^{[1
]}

Savani, Bipin N. ^{[1
]}

Engelhardt, Brian G. ^{[1
]}

Kassim, Adetola ^{[1
]}

Worel, Nina ^{[2
]}

Knobler, Robert ^{[2
]}

Russel, Nigel ^{[4
]}

Socie, Gerard ^{[3
]}

机构：

[1] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA

[2] Med Univ Vienna, Dept Internal Med 1, Vienna, Austria

[3] St Louis Hosp, Serv Hematol Greffe de Moelle, Paris, France

[4] Nottingham Univ Hosp NHS Trust, Univ Nottingham, Div Epidemiol & Publ Hlth, Nottingham, England

来源：

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2013年 / 19卷 / 07期

关键词：

Acute graft-versus-host disease; Steroid-refractory; Extracorporeal photopheresis; Allogeneic hematopoietic cell transplantation; VERSUS-HOST-DISEASE; MARROW; PREDNISONE; SURVIVAL; TERM;

D O I：

10.1016/j.bbmt.2013.04.018

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The optimal therapy for steroid-refractory (SR) acute graft-versus-host disease (aGVHD) is undefined. We studied patients with SR aGVHD, comparing extracorporeal photopheresis (ECP; n = 57) and anticytokine therapy (n = 41). In multivariate analyses, ECP, adjusted for steroid dose (odds ratio, 3.42; P = .007), and grade >II aGVHD (odds ratio, 68; P < .001) were independent predictors of response. ECP therapy, adjusted for conditioning regimen intensity and steroid dose, was associated with superior survival-(hazard ratio [HR), 4.6; P = .016) in patients with SR grade II aGVHD. Grade >II aGVHD at onset of salvage therapy (HR, 9.4; P < .001) and lack of response to therapy (HR, 3.09; P = .011) were associated with inferior survival. These findings require validation in a prospective randomized study. (C) 2013 American Society for Blood and Marrow Transplantation.

引用

页码：1129 / 1133

页数：5

共 50 条

[21] Pharmacokinetics and immunological outcomes of alemtuzumab-based treatment for steroid-refractory acute GvHD
Tey, S-K
Vuckovic, S.
Varelias, A.
Martins, J. P.
Olver, S.
Samson, L.
Sturgeon, E.
Leach, J.
Avery, J.
Nakagaki, M.
Butler, J. P.
Curley, C.
Morton, A. J.
Durrant, S. T.
Kennedy, G. A.
Hill, G. R.
BONE MARROW TRANSPLANTATION, 2016, 51 (08) : 1153 - 1155
[22] Mesenchymal stromal cells plus basiliximab improve the response of steroid-refractory acute graft-versus-host disease as a second-line therapy: a multicentre, randomized, controlled trial
Haixia Fu
Xueyan Sun
Ren Lin
Yu Wang
Li Xuan
Han Yao
Yuanyuan Zhang
Xiaodong Mo
Meng lv
Fengmei Zheng
Jun Kong
Fengrong Wang
Chenhua Yan
Tingting Han
Huan Chen
Yao Chen
Feifei Tang
Yuqian Sun
Yuhong Chen
Lanping Xu
Kaiyan Liu
Xi Zhang
Qifa Liu
Xiaojun Huang
Xiaohui Zhang
BMC Medicine, 22
[23] Mesenchymal stromal cells plus basiliximab improve the response of steroid-refractory acute graft-versus-host disease as a second-line therapy: a multicentre, randomized, controlled trial
Fu, Haixia
Sun, Xueyan
Lin, Ren
Wang, Yu
Xuan, Li
Yao, Han
Zhang, Yuanyuan
Mo, Xiaodong
Lv, Meng
Zheng, Fengmei
Kong, Jun
Wang, Fengrong
Yan, Chenhua
Han, Tingting
Chen, Huan
Chen, Yao
Tang, Feifei
Sun, Yuqian
Chen, Yuhong
Xu, Lanping
Liu, Kaiyan
Zhang, Xi
Liu, Qifa
Huang, Xiaojun
Zhang, Xiaohui
BMC MEDICINE, 2024, 22 (01)
[24] Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial
Jagasia, Madan
Perales, Miguel-Angel
Schroeder, Mark A.
Ali, Haris
Shah, Nirav N.
Chen, Yi-Bin
Fazal, Salman
Dawkins, Fitzroy W.
Arbushites, Michael C.
Tian, Chuan
Connelly-Smith, Laura
Howell, Michael D.
Khoury, H. Jean
BLOOD, 2020, 135 (20) : 1739 - 1749
[25] Response to extracorporeal photopheresis therapy of patients with steroid-refractory/-resistant GvHD is associated with up-regulation of Th22 cells and Tfh cells
Ni, Ming
Wang, Lei
Ding, Yuntian
Gong, Wenjie
Wang, Sanmei
Neuber, Brigitte
Schubert, Maria-Luisa
Sauer, Tim
Huckelhoven-Krauss, Angela
Luft, Thomas
Hegenbart, Ute
Schonland, Stefan
Eckstein, Volker
Wang, Jishi
Kruger, William
Muller-Tidow, Carsten
Dreger, Peter
Schmitt, Michael
Schmitt, Anita
CYTOTHERAPY, 2022, 24 (03) : 311 - 319
[26] Extracorporeal photopheresis in the treatment of acute graft-versus-host disease: A multicenter experience
Batgi, Hikmettullah
Dal, Mehmet Sinan
Erkurt, Mehmet Ali
Kuku, Irfan
Kurtoglu, Erdal
Hindilerden, Ipek Yonal
Kaya, Emin
Berber, Ilhami
Ulas, Turgay
Altuntas, Fevzi
TRANSFUSION AND APHERESIS SCIENCE, 2021, 60 (05)
[27] Therapy of steroid-refractory acute GVHD with CD52 antibody alemtuzumab is effective
Schub, N.
Guenther, A.
Schrauder, A.
Claviez, A.
Ehlert, C.
Gramatzki, M.
Repp, R.
BONE MARROW TRANSPLANTATION, 2011, 46 (01) : 143 - 147
[28] ECP versus ruxolitinib in steroid-refractory acute GVHD - a retrospective study by the EBMT transplant complications working party
Penack, Olaf
Peczynski, Christophe
Boreland, William
Lemaitre, Jessica
Afanasyeva, Ksenia
Kornblit, Brian
Jurado, Manuel
Martinez, Carmen
Natale, Annalisa
Perez-Simon, Jose Antonio
Brunello, Lucia
Avenoso, Daniele
Klein, Stefan
Ozkurt, Zubeyde Nur
Herrera, Concha
Wichert, Stina
Chiusolo, Patrizia
Gavriilaki, Eleni
Basak, Grzegorz W.
Schoemans, Helene
Koenecke, Christian
Moiseev, Ivan
Peric, Zinaida
FRONTIERS IN IMMUNOLOGY, 2023, 14
[29] Propensity Score Matching Analysis Comparing the Efficacy and Steroid Tapering Benefit of Extracorporeal Photopheresis to Best Available Therapy in Third-Line or Beyond Treatment for Chronic GvHD
Novitzky-Basso, Igor
Patriquin, Christopher
Linn, Swe Mar
Chiarello, Caden
Pasic, Ivan
Lam, Wilson
Law, Arjun
Michelis, Fotios V.
Gerbitz, Armin
Viswabandya, Auro
Lipton, Jeffrey
Kumar, Rajat
Mattsson, Jonas
Barth, David
Kim, Dennis Dong Hwan
TRANSPLANTATION AND CELLULAR THERAPY, 2023, 29 (12): : 773.e1 - 773.e10
[30] Extracorporeal photopheresis as second-line treatment therapy in life-threatening primary graft dysfunction following lung transplantation
Robinson, Cecile A.
Inci, Ilhan
Naegeli, Mirjam
Murer, Christian
Schuurmans, Mace M.
Urosevic-Maiwald, Mirjana
Schupbach, Reto
Weder, Walter
Benden, Christian
PEDIATRIC TRANSPLANTATION, 2018, 22 (03)

← 1 2 3 4 5 →